AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease

Prior treatment

• Pregnancy or breastfeeding women; pregnancy test, either urine or blood test must be performed within 7 days prior to the index procedure in woman of child-bearing potential, and must not commit to initiating a pregnancy for 12 weeks after implantation, using effective contraception;
• Unprotected left main as a target lesion unless this lesion is treated with a DES and SCB inflated distally or on a branch or on a different vessel;
• Aorto-ostial target lesion (within 3 mm of the aorta junction); unless this lesion is treated with a DES and SCB inflated distally or on a branch or on a different vessel;
• Stroke within the previous 6 months;
• RVD at the SCB target site \<2.0 mm or \>4.0 mm (by visual estimation and/or QCA); target lesion with RVD larger than 4 mm can be treated with a DES and SCB inflated in other segments of the same or other vessels.

Other illness

• Every known allergy, intolerance or hypersensitivity to any medication used during the procedure and to drugs recommended after the procedure (e.g. aspirin, clopidogrel, ticagrelor, prasugrel);
• Severe chronic kidney disease (glomerular filtration rate\<30 ml/min/1.73 m2);

Lab values

• Platelet count \<50,000cells/mm;

Age

• Age \<18 years;

Other

• Patients participating in another clinical evaluation;
• Cardiogenic shock;
• Thrombus containing lesion;
• Comorbidities with life expectancy \<6 months;
• Target lesion located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft;

• Age \>18 years
• Patients presenting with stable or unstable coronary artery disease (CAD) eligible for percutaneous coronary intervention (PCI) with de novo CAD in one or two separates major epicardial territories and at least one lesion suitable for sirolimus coated balloon (SCB);
• Reference vessel diameter (RVD) at the SCB target site ≥2.0 mm and ≤4.0 mm (by visual estimation and/or quantitative coronary angiography);
• Lesion length at the SCB target site ≥25 mm;
• Successful lesion preparation (full and homogenous pre-dilatation balloon expansion without type C-F dissection and/or TIMI flow=3 at the SCB target site;
• SCB-target lesion located in the same or other vessels treated by drug-eluting stent (DES) implantation;
• Patient able to understand and provide informed consent and comply with all study procedures including 9 months angiographic follow-up.